| Not Yet Recruiting | Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis | Phase 2 | 2026-04-15 |
| Not Yet Recruiting | Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired P Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis | Phase 3 | 2026-04-15 |
| Not Yet Recruiting | ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | Phase 3 | 2026-04-15 |
| Not Yet Recruiting | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat i Pancreatic Cancer Resectable, Pancreatic Cancer | Phase 1 | 2026-03-01 |
| Recruiting | A Study to Assess Anktiva in Patients With Long Covid-19. Long COVID | Phase 2 | 2025-11-14 |
| Recruiting | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma Relapsed B-Cell Non Hodgkin Lymphoma | Phase 2 | 2025-11-11 |
| Not Yet Recruiting | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladde Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | 2025-11-01 |
| Recruiting | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive NMIBC | Phase 1 / Phase 2 | 2025-10-15 |
| Recruiting | ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants NSCLC Stage IV | Phase 3 | 2025-10-01 |
| Recruiting | A Study to Examine Anktiva for the Treatment of COVID-19. Long COVID, Long COVID Syndrome, Long Covid 19 | Phase 2 | 2025-09-04 |
| Recruiting | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma Non Hodgkin's Lymphoma Refractory/Relapsed | Phase 1 | 2025-08-22 |
| Not Yet Recruiting | Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk P High-risk Prostate Cancer | Phase 2 | 2025-06-01 |
| Not Yet Recruiting | Immunotherapy Before and After Surgery High-risk Prostate Cancer | Phase 2 | 2025-05-15 |
| Recruiting | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagoni Platinum-resistant Ovarian Cancer | Phase 2 | 2024-11-06 |
| Recruiting | Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma Refractory/ Relapsed | Phase 1 | 2024-08-23 |
| Recruiting | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma Glioblastoma | Phase 2 | 2024-08-07 |
| Active Not Recruiting | IBRX-042 In Participants With HPV-Associated Tumors HPV-Related Carcinoma | Phase 1 | 2024-06-14 |
| Completed | Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Colle Healthy Subjects | Phase 1 | 2023-10-04 |
| Active Not Recruiting | Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) Non Muscle Invasive Bladder Cancer | — | 2023-08-17 |
| Completed | HCW9218 for Advanced Pancreatic Cancer Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | 2022-10-17 |
| Terminated | THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines COVID-19 | Phase 1 / Phase 2 | 2022-05-05 |
| Withdrawn | COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Base Covid19 | Phase 1 / Phase 2 | 2021-12-01 |
| Withdrawn | COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Tho Covid19 | Phase 1 / Phase 2 | 2021-12-01 |
| Terminated | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior The Advanced Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2021-09-08 |
| Active Not Recruiting | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors Metastatic Solid Tumor | Phase 1 | 2021-06-21 |
| Completed | COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African A Covid19 | Phase 1 | 2021-03-02 |
| Terminated | COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in H Covid19 | Phase 1 | 2021-02-24 |
| Terminated | A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL COVID-19 | Phase 2 / Phase 3 | 2020-12-09 |
| Completed | COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Voluntee COVID-19 | Phase 1 | 2020-10-19 |
| Terminated | Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Me COVID | Phase 1 | 2020-08-03 |
| Terminated | Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 COVID-19 | Phase 1 | 2020-07-22 |
| Active Not Recruiting | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Trea Pancreatic Cancer | Phase 2 | 2020-07-21 |
| Terminated | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed Af Merkel Cell Carcinoma | Phase 2 | 2020-02-19 |
| Withdrawn | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma, B-Cell | Phase 1 | 2019-09-16 |
| Completed | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor | Phase 1 | 2019-07-18 |
| Active Not Recruiting | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Im Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma | Phase 2 | 2018-12-11 |
| Terminated | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Colorectal Cancer Metastatic, mCRC | Phase 1 / Phase 2 | 2018-09-28 |
| Withdrawn | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Triple Negative Breast Cancer (TNBC) | Phase 2 | 2018-09-01 |
| Withdrawn | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Chordoma, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | 2018-08-31 |
| Withdrawn | QUILT-3.088: NANT Pancreatic Cancer Vaccine Metastatic Pancreatic Cancer | Phase 2 | 2018-08-01 |
| Withdrawn | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Met Colorectal Cancer | Phase 1 / Phase 2 | 2018-08-01 |
| Terminated | QUILT-3.080: NANT Pancreatic Cancer Vaccine Pancreatic Cancer | Phase 1 / Phase 2 | 2018-07-17 |
| Withdrawn | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard o Non Small Cell Lung Cancer | Phase 2 | 2018-06-01 |
| Withdrawn | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent | Phase 1 / Phase 2 | 2018-05-25 |
| Terminated | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer Non Small Cell Lung Cancer | Phase 3 | 2018-05-18 |
| Terminated | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2018-03-19 |
| Withdrawn | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2018-02-01 |
| Terminated | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2018-01-09 |
| Terminated | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standar Pancreatic Cancer | Phase 1 / Phase 2 | 2017-12-28 |
| Withdrawn | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Merkel Cell Carcinoma | Phase 1 / Phase 2 | 2017-12-01 |
| Withdrawn | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On Melanoma | Phase 1 / Phase 2 | 2017-12-01 |
| Withdrawn | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20 Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2017-12-01 |
| Withdrawn | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Urothelial Carcinoma | Phase 1 / Phase 2 | 2017-12-01 |
| Withdrawn | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Ovarian Cancer | Phase 1 / Phase 2 | 2017-12-01 |
| Withdrawn | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2017-12-01 |
| Withdrawn | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNB Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2017-12-01 |
| Terminated | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pa Pancreatic Cancer | Phase 1 / Phase 2 | 2017-11-06 |
| Terminated | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Pancreatic Cancer | Phase 1 / Phase 2 | 2017-08-11 |
| Completed | QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors Solid Tumor | Phase 1 | 2017-08-02 |
| Active Not Recruiting | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With A Bladder Cancer | Phase 2 / Phase 3 | 2017-06-02 |
| Terminated | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma | Phase 2 | 2015-09-24 |
| Completed | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Metastatic Small Cell Lung Cancer | Phase 2 | 2015-04-20 |
| Completed | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastati Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | Phase 1 / Phase 2 | 2014-09-02 |
| Completed | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Sol Metastatic Solid Tumors | Phase 1 | 2014-08-01 |
| Active Not Recruiting | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | 2014-07-21 |
| Completed | QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2014-05-12 |
| Completed | A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Kaposi's Sarcoma, HIV Positive, AIDS | Phase 2 | 2014-04-03 |
| Completed | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Glioblastoma | Phase 2 | 2014-03-01 |
| Completed | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | Phase 3 | 2014-01-01 |
| Completed | Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute I Advanced Solid Tumors | Phase 1 | 2012-10-01 |
| Completed | Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubic Advanced Solid Tumor | Phase 1 | 2012-07-01 |
| Completed | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Canc Pancreatic Ductal Adenocarcinoma | Phase 2 | 2012-05-16 |
| Completed | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma | Phase 2 | 2012-01-11 |
| Completed | Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors Malignant Solid Tumour | Phase 1 | 2011-04-01 |
| Available | Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Cou Lymphopenia | — | — |
| Available | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Can NMIBC | — | — |